Company Overview
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -55.6%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -55.58% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +262.00% |
| 6 Months: | -9.95% |
| 3 Months: | +6.89% |
| 1 Month: | +8.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -55.6% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZURA Zura Bio Limited | 5.43 | -4.98 | $515.20M | 0.00% | -74.11% | -40.96% | - | -55.58% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 19.25M | 18.06M | 19.52M | 18.41M | 25.50M |
| Operating Income | - | -19.25M | -18.06M | -19.52M | -18.41M | -25.50M |
| EBITDA | - | -19.25M | -18.05M | -19.50M | -18.40M | -25.48M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -17.44M | -15.99M | -18.04M | -17.18M | -24.22M |
| Tax Provision | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -17.44M | -15.99M | -18.04M | -17.18M | -24.22M |
| Diluted EPS | - | -0.19 | -0.17 | -0.21 | - | -0.22 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 27.16M | 62.64M | 55.19M | 75.25M |
| Operating Income | -27.16M | -62.64M | -55.19M | -75.25M |
| EBITDA | -27.16M | -62.64M | -55.18M | -75.20M |
| Interest Expense | - | - | - | - |
| Pretax Income | -27.33M | -60.56M | -52.40M | -68.65M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -25.74M | -60.36M | -52.40M | -68.65M |
| Diluted EPS | -12.19 | -2.09 | -0.60 | -1.06 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Mar 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.26M | 100.84M | 179.53M | 113.95M |
| Current Assets | - | - | 1.78M | 100.84M | 178.74M | 112.31M |
| Cash & Equivalents | - | - | 1.57M | 99.81M | 176.50M | 109.41M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Total Liabilities | - | - | 27.32M | 21.29M | 19.51M | 12.41M |
| Current Liabilities | - | - | 14.82M | 20.30M | 19.51M | 12.41M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 7.76M | - | - | - |
| Total Equity | - | - | -32.06M | 59.33M | 146.81M | 101.54M |
| Shares Outstanding | - | - | 27.05M | 43.59M | 65.30M | 73.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.20M | -15.05M | -28.08M | -64.81M |
| Investing Cash Flow | -12.00M | -8.00M | -5.08M | -113.00K |
| Financing Cash Flow | 14.77M | 121.29M | 109.84M | -2.16M |
| Capital Expenditure | -12.00M | -8.00M | -5.08M | -113.00K |
| Free Cash Flow | -13.20M | -23.05M | -33.15M | -64.93M |
| Net Change in Cash | 1.57M | 98.24M | 76.69M | -67.09M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 80.3% | -101.7% | -35.7% | -67.6% |
| ROCE % | 284.2% | -77.8% | -34.5% | -74.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.54% | 9.07M | $49.23M |
| 2 | Venrock Adviser, LLC | 6.77% | 6.43M | $34.94M |
| 3 | JPMORGAN CHASE & CO | 4.69% | 4.46M | $24.21M |
| 4 | Great Point Partners LLC | 4.44% | 4.22M | $22.89M |
| 5 | Braidwell LP | 4.20% | 3.99M | $21.66M |
| 6 | Siren, L.L.C. | 3.93% | 3.73M | $20.28M |
| 7 | Commodore Capital Lp | 3.42% | 3.25M | $17.65M |
| 8 | Pfizer Inc | 2.99% | 2.84M | $15.42M |
| 9 | Adage Capital Partners GP L.L.C. | 2.89% | 2.75M | $14.93M |
| 10 | Affinity Asset Advisors, Llc | 2.70% | 2.56M | $13.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZURA
ZURA — Frequently Asked Questions
What is the current share price of Zura Bio Limited (ZURA)?
As of 2026-08-02 19:16 PDT, Zura Bio Limited (ZURA) trades at $5.43 on NasdaqCM. Its 52-week range is $1.41 to $7.04.
What is the market capitalisation of ZURA?
Zura Bio Limited (ZURA) has a market capitalisation of $515.20M on NasdaqCM.
What is the P/E ratio of ZURA?
ZURA trades at a trailing price-to-earnings (P/E) ratio of -4.98. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 2.38.
What is the return on equity (ROE) of ZURA?
ZURA has a return on equity (ROE) of -40.96%. Its return on capital employed (ROCE) is -74.11%.
Is ZURA a good stock to buy?
This page provides a data-driven analysis of Zura Bio Limited (ZURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.